Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) will likely be posting its quarterly earnings results on Thursday, February 6th. Analysts expect Rapport Therapeutics to post earnings of ($0.62) ...

After what many considered a “slow” year for IPOs, January has ushered in a string of biotechs filing to go public. But 2024 wasn’t slow—it was actually quite normal.    | After what many considered a ...

About Rapport TherapeuticsRapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients suffering from ...

Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients suffering from central nervous system (CNS ...

Rapport Therapeutics (RAPP) announced results from its positron emission tomography trial and second multiple ascending dose trial for RAP-219. Data from the trials demonstrated that RAP-219 ...

China Universal Asset Management Co. Ltd. purchased a new position in shares of Rapport Therapeutics (NASDAQ:RAPP – Free Report) during the fourth quarter, according to the company in its most recent ...

BOSTON and SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Rapport Therapeutics, Inc. (Nasdaq: RAPP), please note the references to the ...

BOSTON and SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small ...